- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02929992
Delivery Optimization for Antiretroviral Therapy (The DO ART Study) (DO ART)
Delivery Optimization for Antiretrovial Therapy (The DO ART Study): A Prospective, Interventional, Randomized Study of Community-based ART Initiation, Delivery, and Monitoring in South Africa and Uganda
Study Overview
Status
Detailed Description
Antiretroviral therapy (ART) has tremendous potential to prevent HIV-associated morbidity, mortality and transmission. With reliable ART supply and monitoring, the life expectancy of HIV-positive persons in southern Africa is comparable to that of HIV-negative persons. However, HIV-associated mortality continues to be high among HIV-positive persons not diagnosed and not engaged in care. Of the 35 million persons worldwide who meet WHO (World Health Organization) guidelines for ART, only 15 million are on ART. For already burdened health care systems faced with more than doubling of persons on ART, effective and efficient ART initiation and monitoring strategies are needed. First line ART regimens are once daily oral regimens and well-tolerated, which increases the simplicity of ART delivery in general, including community-based ART delivery a feasible alternative to clinic-based delivery. A priority for optimization of ART delivery is to directly compare and evaluate the impact and cost of community-based ART initiation and resupply to clinic delivery of ART in high prevalence settings in Africa, in order to expand capacity to provide ART coverage.
The investigators have extensive experience with community-based strategies for HIV testing and linkage to care. In a series of studies, the investigators have demonstrated that community-based HIV testing and counseling (HTC) results in >90% knowledge of serostatus and similarly high linkage rates for HIV-positive persons to HIV care. However, the investigators observed bottlenecks within HIV clinics that resulted in delays in ART initiation, particularly for those with higher CD4 counts; only 59% of HIV-positive ART eligible persons were virally suppressed at 12 months, far below the UNAIDS target of 80%. Those findings suggest that community-based strategies for ART initiation and maintenance could address clinic inefficiencies and patient opportunity costs and barriers to optimize ART delivery.
South Africa and Uganda plan to provide decentralized services, including community health workers, CHWs, (known as community health extension workers, CHEWs, in Uganda) conducting HTC and linkage to care and local pharmacy pick-up locations for medication, to meet the challenge of scaling up ART. The investigators proposed Delivery Optimization for Antiretroviral Therapy (The DO ART Study). A rigorous evaluation of an innovative, decentralized ART optimization strategy to safely and cost-effectively deliver ART and monitor viral suppression among HIV-positive persons in South Africa and Uganda. Using a prospective individually-randomized design, the investigators will compare home ART initiation and local mobile van ART resupply to clinic centered care among HIV-positive persons in South Africa and Uganda. Following community sensitization, participants will be recruited through community-based HTC and HIV clinics. HIV-positive persons who are eligible for ART by national guidelines will be randomized to one of three ART delivery arms: (i) Home ART initiation and mobile van ART monitoring and resupply, (ii) A hybrid model of clinic ART initiation with mobile van ART monitoring and resupply, and (iii) Clinic ART initiation, monitoring and resupply - the standard of care (SOC).
The co-primary outcomes are 1) the proportion of HIV-positive persons who initiate ART and achieve viral suppression and 2) cost per HIV-positive person with suppressed HIV viral load at 12 months. The secondary outcomes are safety, social harms, acceptability, the cost-effectiveness of community-based ART delivery, and understanding qualitatively the drivers of engagement in care.
The investigators hypothesize that community-based ART initiation will be acceptable, efficient and improve outcomes, specifically with prompter ART initiation and a higher proportion of HIV-positive persons achieving viral suppression, compared to the standard clinic ART delivery model. Decentralizing HIV care for asymptomatic individuals will expand the overall capacity of the health system to provide care for HIV-positive persons using the existing clinical infrastructure.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Kwa-Zulu Natal
-
Sweetwaters, Kwa-Zulu Natal, South Africa
- HSRC Sweetwaters
-
-
-
-
Bushenyi
-
Kabwohe, Bushenyi, Uganda
- ICOBI
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Reside in the study community for the duration of follow-up
- Able and willing to provide informed consent
- HIV positive and eligible to start ART according to national guidelines
- Not pregnant
- Normal renal function
- Not receiving treatment for active tuberculosis or other opportunistic infections
Exclusion Criteria:
- No separate exclusion criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Home ART initiation
Participants who are eligible to initiate ART will start in the home and will pick up their medication refills from a mobile van.
|
Participants initiate ART use in the home without visiting a clinic
Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
|
Experimental: Hybrid model
Participants will be referred to the clinic to initiate ART, once started they will pick up their medication refills from a mobile van.
|
Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
Participants are referred to the clinic to initiate ART use
|
Active Comparator: Clinic ART initiation, monitoring and resupply
This is the standard of care arm.
Participants will be given a referral to the clinic to initiate ART and will pick up their medication refills from the clinic.
|
Participants are referred to the clinic to initiate ART use
Participants will return to the clinic for ART refill and clinical monitoring.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
HIV viral suppression at 12 months
Time Frame: 12 Months
|
Maximize, through community-based ART initiation and maintenance, the proportion of HIV-positive ART eligible persons who achieve viral suppression at 12 months
|
12 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Measurement of safety across study arms
Time Frame: 1 month, 3 months, 6 months, 9 months, 12 months
|
Compare the rates of clinical adverse events across study arms.
|
1 month, 3 months, 6 months, 9 months, 12 months
|
Estimate cost-effectiveness of each arm
Time Frame: 12 months
|
Estimate the cost-effectiveness for community-based ART initiation compared to clinic-based programs, using mathematical models and study results.
|
12 months
|
Qualitative review
Time Frame: 1 month, 3 months, 6 months, 9 months, 12 months
|
Use qualitative methods to assess "how" and "why" community-based strategies of ART initiation, re-supply and monitoring impact viral suppression and other study outcomes.
|
1 month, 3 months, 6 months, 9 months, 12 months
|
Minimize the cost of achieving viral suppression
Time Frame: 12 months
|
Minimize the cost per HIV-positive person achieving viral suppression and retention in the continuum of HIV care through community-based strategies compared to clinic standard of care
|
12 months
|
Measurement of social harms
Time Frame: 12 months
|
Compare the rates of reported social harms across study arms.
|
12 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ruanne Barnabas, MBChB, DPhil, Assistant Professor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 50607
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRecruitingHIV | HIV Testing | HIV Linkage to Care | HIV TreatmentUnited States
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationCompletedPartner HIV Testing | Couple HIV Counseling | Couple Communication | HIV IncidenceCameroon, Dominican Republic, Georgia, India
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement and other collaboratorsUnknownHIV | HIV-uninfected Children | Children Exposed to HIVCameroon
-
University of MinnesotaWithdrawnHIV Infections | HIV/AIDS | Hiv | AIDS | Aids/Hiv Problem | AIDS and InfectionsUnited States
-
CDC FoundationGilead SciencesUnknownHIV Preexposure Prophylaxis | HIV ChemoprophylaxisUnited States
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London; University... and other collaboratorsRecruiting
-
Massachusetts General HospitalNational Institute of Mental Health (NIMH); Fenway Community Health; Tuberculosis...CompletedHIV/STI Risk | HIV/STI IncidenceUnited States, India
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
University of WashingtonNational Institute of Mental Health (NIMH)RecruitingHIV Prevention | HIV Preexposure Prophylaxis | ImplementationKenya
-
University of Maryland, BaltimoreWithdrawnHiv | Kidney Transplant | HIV Reservoir | CCR5United States
Clinical Trials on ART initiation in the home
-
Liverpool School of Tropical MedicineLondon School of Hygiene and Tropical Medicine; Kamuzu University of Health... and other collaboratorsCompleted
-
IP Santé DomicileUnknown
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA); University of Washington; Seattle Children... and other collaboratorsCompleted
-
Olivier HugliCompletedPain, Acute | Anxiety AcuteSwitzerland
-
The Hospital for Sick ChildrenRecruitingSleep-Disordered BreathingCanada
-
Brigham and Women's HospitalHarvard Medical School (HMS and HSDM); Weill Medical College of Cornell University and other collaboratorsUnknown
-
University of California, Los AngelesBoston University; Charles University, Czech Republic; Bill and Melinda Gates... and other collaboratorsActive, not recruiting
-
National University Health System, SingaporeNational University of SingaporeCompleted
-
National Center for Research Resources (NCRR)UnknownHIV InfectionsUnited States
-
Cerebra MedicalUniversity of ManitobaSuspended